Cartesian Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $435.02 Mil.
During the past 12 months, Cartesian Therapeutics's average Total Assets Growth Rate was -2.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 91.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 88.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 48.30% per year.
During the past 11 years, Cartesian Therapeutics's highest 3-Year average Total Assets Growth Rate was 104.30%. The lowest was -7.50%. And the median was 56.45%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cartesian Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics (NAS:RNAC) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cartesian Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cartesian Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Cartesian Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RNAC has been successfully added to your 